M-CPP
Eating Behavior
University of BirminghamSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Eating Behavior cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide University Hospital Sestre Milosrdnice | Phase 4 | BB |
2-Bromo-?-ergocryptine University of North Carolina, Chapel Hill | Phase 3 | BB |
Rimonabant Sanofi | Phase 3 | CC |
PYY(3-36) Gila Therapeutics, Inc. | Phase 1 | CC |
LAC VACCINUM Mount Saint Vincent University | N/A | D |
View all 10 →
Same molecule, other indications
M-CPP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →